在慢性病和2型糖尿病中,芬瑞和左心室缩
Gerasimos Filippatos1, Stefan D Anker2, George L Bakris3
1National and Kapodistrian University of Athens, School of Medicine Department of Cardiology, Attikon University Hospital, Athens, Greece.
ESC heart failure
|September 3, 2024
概括
费伦在患有慢性病和2型糖尿病的患者中显示出整体的心血管和益,无论左心室缩 (LVH) 是否存在. 然而,LVH预测心力衰竭住院病例的减少更大.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
背景情况:
- 左心室缩 (LVH) 增加了心血管疾病 (CV) 的风险,发病率和死亡率.
- 患有慢性病 (CKD) 和2型糖尿病 (T2D) 的患者经常有高血压和高患病率的LVH.
- 烯是一种非类固醇矿物质皮质类受体对抗剂,目前正在研究其对CKD和T2D患者的CV和的影响.
研究的目的:
- 为了探索费内伦对CKD和T2D患者的CV和的影响.
- 根据基线左心室缩 (LVH) 的存在或不存在来分层分析.
- 评估 LVH 是否会改变芬瑞对心血管和脏的治疗效果.
主要方法:
- 来自FIDELIO-DKD和FIGARO-DKD第三阶段研究 (FIDELITY) 的汇总数据的分析.
- 患者根据研究人员报告的LVH在基线的心电图 (ECG) 发现进行了分层.
- 主要结局包括复合CV事件 (CV死亡,心脏病发作,中风,心力衰竭住院治疗) 和复合事件 (功能衰竭,持续的EGFR下降,相关死亡).
主要成果:
- 在13026名患者中,9.6%的患者有基线LVH;96.5%的患者有高血压.
- 费伦对复合心血管和结局的相对风险降低与基线LVH没有显著改变 (P相互作用 = 0.1075和0.1782,分别).
- 与没有 (P相互作用 = 0.0024) 相比,在患有LVH的患者中,观察到费内伦治疗心力衰竭 (HHF) 的住院时间显著减少.
结论:
- 费内伦对心血管和脏的整体益处在患有和没有基线LVH的患者中是一致的.
- 包括高血症在内的安全调查结果在LVH亚组之间是相似的.
- 基线LVH可能预测芬瑞对减少心力衰竭住院的治疗效果更大.
更多相关视频
08:505/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
23.6K
10:37Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
103
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
01:11Renal Failure: Dose Adjustments
69
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
69
01:25Antihypertensive Drugs: Direct Renin Inhibitors
511
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
511
01:17Factors Affecting Renal Clearance: Renal Impairment
62
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
62
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
510
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
510